Treating Narcolepsy Around the Clock
New data suggest that targeting the underlying orexin deficiency can improve a broad spectrum of narcolepsy type 1 symptoms, from daytime cognition to nighttime sleep architecture.
Category: Pharmaceuticals
Pharmaceuticals
Latest
Pharmaceuticals
Latest
Semaglutide Associated With Lower Incidence of OSA in Post Hoc Analysis
A post hoc analysis of the SELECT trial suggests that semaglutide 2.4 mg is associated with a significantly lower incidence of obstructive sleep apnea in adults with overweight or obesity and established cardiovascular disease. While these findings are promising, Novo Nordisk notes that semaglutide is not currently approved to treat obstructive sleep apnea and further research is required.
Pharmaceuticals
Latest
How to Afford CPAP + GLP-1 Polytherapy
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
Prescription Drugs
Latest
Steady-State Pharmacokinetics for Sublingual Tablet That Targets Nonrestorative Sleep Linked to Fibromyalgia
The peer-reviewed study highlights how the sublingual cyclobenzaprine formulation targets nonrestorative sleep and bypasses first-pass metabolism.
Over-the-Counter Treatments
Latest
Saline Nasal Spray Shows Efficacy in Treating Pediatric Sleep-Disordered Breathing
A new Australian study finds that a simple saline nasal spray can resolve symptoms of obstructive sleep-disordered breathing in children, potentially reducing the need for surgery and specialist care.
Emerging Compounds
Latest
Alkermes to Present Sustained Efficacy Data for Alixorexton in Narcolepsy Type 1
Phase 2 Vibrance-1 study extension shows sustained improvements in patient-reported disease severity, cognitive functioning, and fatigue.